Clinical trials: Dermatitis Atopic
Dermatitis Atopic
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant…
- Trial name
- GLOBOSTAD (NCT03992417)
- Testing
- Dupilumab SAR231893 (REGN668)
- Where
- 105 sites in Argentina, Australia and 20 more
- Volunteers
- 955 people
- Sponsor
- Sanofi
Dermatitis, Atopic
Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Allergic Skin Inflammation (P03475)
The purpose of this study was to test the effectiveness and safety of desloratadine (Aerius) syrup in children with allergic skin inflammation. Patients took desloratadine syrup once a day for 28 days.
- Trial name
- NCT00817076
- Testing
- desloratadine
- Volunteers
- 40 people
- Sponsor
- Organon and Co
Asthma, Dermatitis, Atopic
A Long-Term Examination of Asthma From Childhood Through Adolescence
Asthma is a common disease that is often diagnosed in childhood. In some teenagers, asthma symptoms disappear and treatment can be stopped; however, for some of these people, asthma symptoms return in adulthood.
- Conditions
- Asthma, Dermatitis, Atopic, Rhinitis, Urticaria
- Trial name
- NCT00541255
- Where
- United Kingdom
- Volunteers
- 1,313 people, healthy volunteers welcome
- Sponsor
- Isle of Wight NHS Trust
Atopic Dermatitis
Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis
Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of pimecrolimus cream will be evaluated in Japanese adult patients with atopic…
- Trial name
- NCT00232011
- Testing
- Pimecrolimus Cream 1%
- Where
- Japan
- Volunteers
- 160 people
- Sponsor
- Novartis
Atopic Dermatitis (AD)
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
The primary objective of the study was to assess the efficacy of Dupilumab, compared to placebo, in adult patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01979016
- Testing
- Dupilumab, Background treatment
- Where
- 4 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis, Eczema
Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms
This interventional, double-blind, randomized, placebo-controlled study aims to evaluate the effect of a marine by-product hydrolysate supplementation on the reduction of atopic dermatitis symptoms.
- Trial name
- NCT06268847
- Testing
- ACT01, ACT02
- Where
- Spain
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Abyss Ingredients
Atopic Dermatitis
Apremilast for Atopic Dermatitis - A Pilot Study in Adults
The purpose of this study is to obtain preliminary data regarding the safety and tolerability of apremilast in AD to support the design of larger controlled studies.
- Trial name
- NCT01393158
- Testing
- Apremilast
- Volunteers
- 16 people
- Sponsor
- Oregon Health and Science University
Atopic Dermatitis
Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis
This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic dermatitis.
- Trial name
- NCT04753034
- Testing
- TER-101, Vehicle
- Where
- 12 sites in United States
- Volunteers
- 63 people
- Sponsor
- Teres Bio, Inc.
Atopic Dermatitis, Atopic Eczema
The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover
The investigators believe that the emerging epidemiological evidence connecting topical use of corticosteroids to the development of type 2 diabetes and osteoporosis point to potentially massive, yet clinically unacknowledged…
- Trial name
- NCT04114097
- Testing
- Protopic, tacrolimus ointment 0.1%
- Where
- Denmark
- Volunteers
- 36 people
- Sponsor
- Jacob Thyssen
Atopic Dermatitis
Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj
A multi-center, open, long-term follow-up study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results from the K0104 Extension Study
- Trial name
- NCT04730024
- Testing
- Not applicable(observational study)
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis With a History of Eczema Herpeticum, Atopic Dermatitis Without a History of Eczema Herpeticum
Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum
This study investigates whether blood monocytes' surface bound- immunoglobulin E affects the innate immune responses against herpes simplex viruses in atopic dermatitis patients with eczema herpeticum.
- Conditions
- Atopic Dermatitis With a History of Eczema Herpeticum, Atopic Dermatitis Without a History of Eczema Herpeticum, Health Controls Without Atopy
- Trial name
- NCT04060550
- Testing
- Xolair
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Pruritus in Patients With Atopic Dermatitis
Safety and Efficacy of DNK333 in Atopic Dermatitis Patients
This study will assess the safety and efficacy of DNK333 in patients with atopic dermatitis suffering from pruritus, who require systemic treatment of the disease.
- Trial name
- NCT01033097
- Testing
- DNK333 5 mg, DNK333 25 mg, DNK333 100 mg
- Where
- 5 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis
The purpose of this study is to document the timing of improvement in atopic dermatitis symptoms and severity following the application of crisaborole ointment 2% in patients 2 years or older with mild to moderate atopic…
- Trial name
- NCT04214197
- Testing
- Crisaborole 2% Top Oint
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Massachusetts General Hospital
Chronic Eczema, Psoriasis
Revitalization of Damaged Skin Due to Chronic Skin Diseases
Chronic skin disease lead to skin damage and disfiguring to the patient skin. Sometimes, achieving normal skin is not possible by the normal traditional treatment, this study is focusing on use of ACE CSD formula which is mixture…
- Conditions
- Chronic Eczema, Psoriasis, Atopic Dermatitis
- Trial name
- NCT03485560
- Testing
- ACE CSD
- Where
- 2 sites in Serbia, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Ace Cells Lab Limited
Atopic Dermatitis, Eczema
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
The goal of this observational study is to learn about exposure to tralokinumab during pregnancy, as well as atopic dermatitis (AD) during pregnancy.
- Trial name
- PROTECT (NCT05938478)
- Testing
- Tralokinumab
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- University of California, San Diego
Infantile Colics, Constipation
Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete
This is a randomized, single-blind, placebo-controlled study to evaluate the efficacy of the dietary supplement BioAmicus Complete (oral drops; a mixture of 10 strains of lacto- and bifidobacteria) in managing functional…
- Conditions
- Infantile Colics, Constipation, Infantile Diarrhea, Atopic Dermatitis
- Trial name
- NCT07444008
- Testing
- BioAmicus Complete
- Where
- Russia
- Volunteers
- 140 people
- Sponsor
- NovoNatum Ltd
Atopic Dermatitis
A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants
The goal of this intervention study is to evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HXN5003 in Healthy Participants.The main parameters it aims to answer are: 1.
- Trial name
- NCT07549750
- Testing
- HXN5003
- Where
- Australia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Atopic Dermatitis
A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis
This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 injection in the treatment of patients with moderate to severe atopic dermatitis.
- Trial name
- NCT06383468
- Testing
- AK120
- Where
- 59 sites in China
- Volunteers
- 420 people
- Sponsor
- Akeso
Atopic Dermatitis
A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
Researchers are looking for a better way to treat atopic dermatitis (AD), an often long-lasting inflammation of the skin. Atopic dermatitis, also called eczema, is causing patches of skin to become swollen, red, cracked, and…
- Trial name
- Damask (NCT05656911)
- Testing
- Zabedosertib (BAY1834845)
- Where
- 22 sites in United States, Czechia and 5 more
- Volunteers
- 77 people
- Sponsor
- Bayer
Atopic Dermatitis
A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)
The purpose of this study was to evaluate the pharmacokinetics and safety of nemolizumab in adolescent participants with AD.
- Trial name
- NCT03921411
- Testing
- Nemolizumab
- Where
- 10 sites in United States
- Volunteers
- 20 people
- Sponsor
- Galderma R&D
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.